Survival of localized NSCLC patients without active treatment or treated with SBRT

Figures & data

Table 1. Patients’ characteristics.

	All patients (n = 209)	NoTx group (n = 73)	SBRT group (n = 136)	p Value
Sex				.77
Female	113 (54%)	38 (52%)	75 (55%)
Male	96 (46%)	35 (48%)	61 (45%)
Age (years)				<.001
Mean (range)	74.4 (49–90)	77.8 (54–89)	72.5 (49–90)
ECOG PS				.88
0–1	95 (47%)	31 (46%)	64 (47%)
2+	109 (53%)	37 (54%)	72 (53%)
CCI				.23
0–1	104 (50%)	33 (45%)	71 (53%)
2–3	67 (32%)	29 (40%)	38 (28%)
4+	37 (18%)	11 (15%)	26 (19%)
Tumour diameter mean				.58
cm (range)	3.0 (0.7–5.0)	3.0 (0.7–5.0)	3.1 (1.2–5.0)
Histology/cytology				.004
Adenocarcinoma	101 (48%)	24 (33%)	77 (57%)
Squamous cell carcinoma	68 (33%)	30 (41%)	38 (28%)
Other	40 (19%)	19 (26%)	21 (15%)
Pack years				.77
Number of packyears (range)	41 (0–180)	42 (0–180)	41 (0–130)
Lung function
FEV1 (L), median	1.42 (0.27–3.83)	1.42 (0.39–3.27)	1.42 (0.27–3.83)	.85
FEV1%pred, median	61 (12–142)	60 (15–105)	57 (12–127)	.29
FEV1 z-score, median	−2.38 (−5.54 to 1.47)	−2.13 (−4.73 to 0.29)	−2.47 (−5.54 to 1.47)	.09
Year of diagnosis				<.001
2007–2009	60	29 (48%)	31 (52%)
2010–2011	60	26 (43%)	34 (57%)
2012–2013	89	18 (20%)	71 (80%)
Staging procedures
Bronchoscopy	111 (53%)	44 (60%)	67 (50%)	.15
CT of thorax	207 (99%)	71 (97%)	136 (100%)	.12
PET/CT	180 (86%)	47 (64%)	133 (98%)	<.001
EBUS/mediastinoscopy	83 (40%)	20 (27%)	63 (46%)	.01

ECOG PS, Eastern Cooperative Oncology Group definition of performance status; CCI, Charlson Comorbidity Index; FEV1, forced expiratory volume in 1 s; FEV1%,- FEV1 of expected.

Missing data: Packyears for 19 patients, PS for five patients, CCI for one patient, FEV1 and FEV1%pred for 15 and 19 patients. All patients with missing data are in the untreated group except one patient with unreported CCI in the SBRT group.

Figure 1. Kaplan–Meier survival curves of overall survival for the SBRT group and the NoTx group before PSM.

Table 2. Proportional hazards model for mortality among the total study population in univariate and multivariate models.

	Univariate model			Multivariate model
	HR	p Value	95% CI	HR	p Value	95% CI
Age	1.02	.01	1.01–1.04	–	–	–
SBRT	0.27	<.001	0.20–0.38	0.25	<.001	0.17–0.35
T-diameter ≥3 cm	1.35	.06	0.98–1.84	1.64	.003	1.18–2.27
Male sex	0.98	.66	0.72–1.34	–	–	–
ECOG PS 2+	1.55	.01	1.12–2.14	1.72	.001	1.24–2.38
Packyears	1.00	.71	0.99–1.01	–	–	–
FEV1 reduction grade				–	–	–
1 none to mild (reference)	1.00	–	–
2 moderate	1.06	.82	0.65–1.73
3 moderate severely	0.99	.97	0.62–1.58
4 severe	0.88	.61	0.55–1.41
5 very severe	0.92	.78	0.51–1.66
Adenocarcinoma	0.87	.39	0.64–1.19	–	–	–
PET/CT scan	0.37	<.001	0.24–0.56	–	–	–
Charlson Comorbidity Index
CCI 0–1 (reference)	1.00	–	–
CCI 2–3	1.33	.11	0.94–1.89
CCI >3	1.22	.35	0.80–1.86

Figure 2. Kaplan–Meier survival curves of overall survival for the SBRT group and the NoTx group after PSM.